Target intelligence / Profile preview

Rotavirus outer capsid glycoprotein VP7 (VP7)

Target
VP7
Molecular classification
Viral protein, Glycoprotein, Capsid protein, Other
01

Overview

Rotavirus outer capsid glycoprotein VP7 is a major structural protein of the rotavirus virion, forming the outer shell of the triple-layered viral particle. It functions as a calcium-binding protein that plays a critical role in viral attachment and entry into host enterocytes, interacting with cell surface receptors after initial binding by the VP4 spike protein. VP7 is the primary determinant of the G (glycoprotein) serotype classification of rotaviruses, with the G2 serotype being one of the most prevalent causes of severe diarrheal disease in infants and young children worldwide. As a major target of neutralizing antibodies, the G2 antigen is incorporated into several live-attenuated and reassortant rotavirus vaccines, such as the pentavalent vaccine RotaTeq. Immunization with these vaccines elicits homotypic and heterotypic immune responses, protecting against severe rotavirus-induced gastroenteritis. However, the target faces challenges from antigenic drift, where specific amino acid substitutions in the antigenic regions of VP7 (such as the D96N mutation) can lead to vaccine escape and altered serotype prevalence.

Other names
Rotavirus serotype G2 antigenRotavirus G2 antigenRotavirus VP7 glycoproteinOuter capsid glycoprotein VP7Major neutralization glycoprotein VP7G2 serotype VP7 protein
02

Mechanism of action

Active immunization by presenting the G2 VP7 antigen to the host immune system, eliciting the production of neutralizing antibodies and memory B cells that target the outer capsid of the virus, thereby preventing viral attachment, entry, and subsequent replication in host enterocytes.

03

Biological functions

Immune responseHost cell attachmentViral entryOther
04

Disease associations

Infection
05

Safety considerations

Intussusception (a rare but serious risk associated with live rotavirus vaccines)Vaccine-induced gastroenteritis (mild, transient diarrhea or vomiting)Vaccine virus shedding (potential transmission of the live-attenuated virus to immunocompromised contacts)Antigenic drift and vaccine escape mutants (mutations in VP7 antigenic regions, such as the D96N substitution, which can lead to vaccine escape and reduced efficacy)
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Anti-rotavirus IgA antibodiesSerum neutralizing antibody titersRotavirus antigen in stoolG2-specific neutralizing antibodies

Beyond the preview

Go deeper on Rotavirus outer capsid glycoprotein VP7 (VP7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rotavirus outer capsid glycoprotein VP7 (VP7).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call